Lu-XT033 not checked

Sinotau Pharmaceutical Group

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of \[177Lu\] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval .”In the company’s words, NCT06081686 on ClinicalTrials.gov
Tested for
Prostate Cancer
Main trialPhase 1/2
“This was a multicenter, open-label, phase I/II study to evaluate the safety and tolerability, radiation dosimetry and pharmacokinetic characteristics, and efficacy of \[177Lu\] Lu-XT033 injection in patients with metastatic prostate cancer, including a phase I study and a phase II extension study.”In the company’s words, NCT06081686 on ClinicalTrials.gov

Other drugs for Prostate Cancer

All 194 drugs for Prostate Cancer

Coming up1

Changes2

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 31 Dec 2027 Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Lu-XT033

Following is part of Solo: you see every change to Lu-XT033 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in